Related Experiment Video

Updated: Mar 1, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.3K

Targeting post-translational histone modifications for the treatment of non-medullary thyroid cancer

Marilena Celano1, Catia Mio2, Marialuisa Sponziello3

  • 1Department of Health Sciences, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy.

Molecular and Cellular Endocrinology
|June 6, 2017
PubMed

Insights

Histone modification modulators show promise for treating thyroid cancer, especially drug-resistant types. These agents re-differentiate and inhibit tumor proliferation, offering new therapeutic avenues.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Genomic and epigenetic alterations are key in cancer development.
  • Post-translational histone modifications are implicated in thyroid cancer.
  • Histone modifications represent novel therapeutic targets for resistant tumors.

Purpose of the Study:

  • To review preclinical and clinical findings on histone-activity modulators in thyroid cancer.
  • To highlight their role as re-differentiating and anti-proliferating agents.
  • To discuss their efficacy alone and in combination with other targeted drugs.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of histone modification patterns in thyroid malignancies.
  • Evaluation of therapeutic effects of histone-activity modulators.

Main Results:

  • Histone modification abnormalities are present in thyroid cancer.
  • Histone-activity modulators demonstrate re-differentiating and anti-proliferating effects.
  • Combinatorial therapies show differential effects compared to monotherapy.

Conclusions:

  • Histone-activity modulators are promising for thyroid cancer treatment.
  • These agents offer potential for overcoming resistance to conventional therapies.
  • Further clinical investigation is warranted for their therapeutic application.
Keywords:
Epigenetic drugsEpigenetic writersHistone deacetylase and acetyl transferaseThyroid cancer cellserasers and readers

More Related Videos

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.7K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
8.4K
Histone Modification02:32

Histone Modification

4.7K
Histone Modification02:32

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
16.6K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.5K